Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120263 | 0.84 | LMNA (0.50) | LMNAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL14671141 | 0.83 | LMNA (0.52) | LMNAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL12040437 | 0.83 | CSF1R (0.38) | LMNAMAPTPOLBKDM4EHTT | |
| SCHEMBL837653 | 0.80 | MAPT (0.43) | LMNAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL21503710 | 0.79 | KMT2A (0.50) | LMNAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL4422519 | 0.79 | MAPT (0.43) | LMNAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL34473052 | 0.79 | LMNA (0.45) | LMNAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL15638959 | 0.76 | KDM4E (0.56) | LMNAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL22111912 | 0.76 | LMNA (0.39) | LMNAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL2187271 | 0.76 | LMNA (0.42) | LMNAMAPTPOLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4408427-A1 | SYSTEM AND METHOD FOR STATIC AND DYNAMIC MRI SHIMMING | Merck Sharp & Dohme LLC (US) | 2024-08-07 | — | — | EP | claimed |
| WO-2023055679-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-04-06 | — | — | WO | claimed |
| WO-2025133915-A1 | COMPOUNDS WHICH BIND TO PNPLA3I148M AND THEIR USE TO TREAT LIVER DISEASES | NOVARTIS AG (CH) | 2025-06-26 | — | — | WO | disclosed |
| US-11737463-B2 | Pyridine and pyrazine compounds | BASF SE (DE) | 2023-08-29 | — | — | US | disclosed |
| US-20210145002-A1 | PYRIDINE AND PYRAZINE COMPOUNDS | BASF SE (DE) | 2021-05-20 | — | — | US | disclosed |
| WO-2016051193-A1 | COMPOUNDS USEFUL AS CSF1 MODULATORS | REDX PHARMA PLC (GB) | 2016-04-07 | — | — | WO | disclosed |
| US-20140364415-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-12-11 | — | — | US | disclosed |
| US-8846698-B2 | Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors | PFIZER LIMITED (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2694509-A1 | PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | Pfizer Limited (GB) | 2014-02-12 | — | — | EP | disclosed |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| WO-2012137089-A1 | PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | PFIZER LIMITED (GB) | 2012-10-11 | — | — | WO | disclosed |
| EP-1061908-A4 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1024696-A4 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | MERCK & CO INC (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1079863-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LTD. (GB) | 2001-03-07 | — | — | EP | disclosed |
| EP-1061908-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-1024696-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | Merck & Co., Inc. (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999059635-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LIMITED (GB) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999045913-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999020110-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737463-B2 | Pyridine and pyrazine compounds | NDUFS5, IL5, NDUFS4 | LMNA 4043/4885MAPT 1613/4885POLB 2588/4885 |
| US-20210145002-A1 | PYRIDINE AND PYRAZINE COMPOUNDS | NDUFS5, IL5, NDUFS4 | LMNA 4043/4885MAPT 1613/4885POLB 2588/4885 |
| US-20140364415-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | DMPK, DTYMK, MUSK | LMNA 2709/4885MAPT 1597/4885POLB 1288/4885 |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | DMPK, DTYMK, MUSK | LMNA 2709/4885MAPT 1597/4885POLB 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.